查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1601160

胰臟癌治疗市场：按类型、产品和最终用户划分 - 全球预测 2025-2030

Pancreatic Cancer Therapeutics Market by Type (Endocrine Pancreatic Cancer, Exocrine Pancreatic Cancer), Product (Chemotherapy, Gene Therapy, Immunotherapy), End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年胰臟癌治疗市场规模为46.7亿美元，预计2024年将达51.4亿美元，复合年增长率为9.95%，预计2030年将达90.9亿美元。

胰臟癌治疗市场是肿瘤学领域的重要组成部分，专注于开拓胰臟恶性细胞的治疗方法。这个市场的范围正在扩展到标靶治疗、化疗、放射线治疗、免疫治疗和基因治疗等新选择。该市场的成长是由胰臟癌盛行率上升、人口老化、意识增强以及医学研究的进步所推动的。对这些疗法的需求源于与胰腺癌相关的历史上较低的生存率以及改善患者预后的创新疗法的迫切需求。典型的最终用户包括医院、癌症研究中心和参与研究的製药公司。

主要市场统计
基准年[2023] 46.7亿美元
预测年份 [2024] 51.4亿美元
预测年份 [2030] 90.9亿美元
复合年增长率（%） 9.95%

影响市场的主要成长要素包括诊断程序的技术进步、强大的药物管道、不断增加的研发投资以及政府支持癌症研究的措施。此外，生物技术公司和研究机构之间的合作正在创造潜在的机会，特别是在个人化医疗和生物标记发现方面。利用这些机会的建议包括建立策略伙伴关係、专注于精准医疗等利基领域，以及加速有前景的治疗方法的临床试验。

然而，这个市场面临着治疗成本高、监管核准严格以及早期诊断挑战等限制，影响了患者获得治疗的机会。竞争对手之间的敌对关係以及药物开发上的大量时间投入构成了额外的障碍。公司可以透过将研究重点放在开发微创治疗方法、改进药物输送系统和探索新的联合治疗来推动创新。此外，还有望利用人工智慧和巨量资料分析来提高药物发现效率。

总之，虽然胰臟癌药物市场透过技术进步和合作拥有巨大的成长机会，但解决成本障碍和监管挑战至关重要。治疗创新和资料主导的方法将为重大突破铺平道路，推动业务成长并改善患者照护。

市场动态：快速发展的胰臟癌药物市场的关键市场洞察

供需的动态交互作用正在改变胰臟癌药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球胰臟癌盛行率不断上升
    • 政府努力扩大胰臟癌治疗选择
  • 市场限制因素
    • 由于副作用而难以获得药物召回和报销选项
  • 市场机会
    • 提高胰臟癌药物疗效的研究措施和进展
    • 核准胰臟癌治疗和核准罕见癌症药物
  • 市场挑战
    • 胰臟癌治疗方案的局限性和併发症以及缺乏训练有素的医疗专业人员

波特五力：驾驭胰臟癌药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解胰臟癌药物市场的外部影响

外部宏观环境因素在塑造胰臟癌治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解胰臟癌治疗药物市场的竞争状况

胰臟癌治疗药物市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵胰臟癌治疗市场供应商的绩效评估

FPNV定位矩阵是评估胰臟癌治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

本报告提供了涵盖关键重点领域的全面市场分析：

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球胰臟癌发生率正在上升
      • 政府努力扩大胰臟癌治疗选择
    • 抑制因素
      • 难以获得危险药品召回和报销选择
    • 机会
      • 提高胰臟癌药物疗效的研究倡议和进展
      • 核准胰臟癌药物和核准用于癌症治疗的孤儿药
    • 任务
      • 胰臟癌治疗方案的局限性和併发症以及缺乏训练有素的医疗专业人员
  • 市场区隔分析
    • 类型：外分泌胰臟癌的快速进展需要快速部署治疗方案
    • 产品：扩大核准的化疗方案的数量
    • 最终用途：扩大胰臟癌治疗研究机构之间的合作与研发活动
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章胰臟癌治疗药物市场：依类型

  • 内分泌胰臟癌
  • 外分泌胰臟癌

第七章胰臟癌治疗药物市场：副产品

  • 化疗
  • 基因治疗
  • 免疫疗法
  • 放射治疗
  • 外科手术
  • 标靶治疗

第八章胰臟癌治疗药物市场：依最终用途分类

  • 癌症中心/诊所
  • 医院
  • 调查机构

第九章美洲胰臟癌药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区胰臟癌治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲胰臟癌药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Trishula Therapeutics 开始在第一线转移性胰臟癌患者中进行抗 CD39 抗体 TTX-030 的 2 期试验
    • Risata 获得治疗胰臟癌的孤儿药资格
    • PanCAN 宣布新的高级研究投资
    • Prestige Biopharma 与 Imagion Biosystems 签署合作协议，开发胰臟癌早期诊断平台
    • TriSalus Life Sciences 完成与 MedTech Acquisition Corporation 的合併
    • 百时美施贵宝透过收购 Mirati Therapeutics 加强肿瘤学产品组合併使其多元化
    • 安斯泰来製药 ( Astellas Pharma) 和 Poseida Therapeutics 宣布策略性投资，支持 Poseida 革新癌细胞疗法的努力
    • FDA 指定 Zenocutuzumab 突破性治疗 NRG1+ 胰臟癌
    • FDA核准TME Pharma 胰臟癌治疗试验的 IND
    • GenesisCare 在 Lee Health 区域癌症中心安装 ViewRay MRIdian MRI 导引放射治疗系统
    • 国家拨款 300 万美元用于胰臟癌研究
    • Leap Therapeutics 收购 Flame Biosciences
    • Caladrius Biosciences 和 Cend Therapeutics 宣布完成合併并组成 Lisata Therapeutics
    • Fes Therapeutics 融资 4700 万美元用于推进癌症临床试验
    • Astra Zeneca-默克公司的LYNPARZA获得欧盟核准用于胰臟癌治疗

公司名单

  • Abbvie Inc.
  • Amgen Inc.
  • Ascentage Pharma Group
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • CH Boehringer Sohn AG & Co. KG
  • Carl Zeiss AG
  • Carrick Therapeutics Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Faeth Therapeutics, Inc.
  • FUJIFILM Holdings Corporation
  • GE HealthCare Technologies, Inc.
  • GenesisCare
  • GlaxoSmithKline PLC
  • Hetero Healthcare Limited
  • ImmunityBio, Inc.
  • Innovent Biologics Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Mitsubishi Heavy Industries, Ltd.
  • NGM Biopharmaceuticals, Inc.
  • NovalGen
  • Novartis AG
  • PanTher Therapeutics, Inc.
  • Pfizer, Inc.
  • RenovoRx, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zentalis Pharmaceuticals, Inc.
Product Code: MRR-4342CA32667F

The Pancreatic Cancer Therapeutics Market was valued at USD 4.67 billion in 2023, expected to reach USD 5.14 billion in 2024, and is projected to grow at a CAGR of 9.95%, to USD 9.09 billion by 2030.

The pancreatic cancer therapeutics market is a critical segment of the oncology sector, focused on developing treatments that target malignant cells in the pancreas. The scope of this market extends to targeted therapies, chemotherapy, radiation therapy, and emerging options such as immunotherapy and gene therapy. This market's growth is driven by the rising prevalence of pancreatic cancer, an aging population, increased awareness, and advancements in medical research. The necessity of these therapeutics stems from the historically low survival rate associated with pancreatic cancer and the urgent need for innovative treatments that improve patient outcomes. Major end-users include hospitals, cancer research centers, and pharmaceutical companies involved in R&D.

KEY MARKET STATISTICS
Base Year [2023] USD 4.67 billion
Estimated Year [2024] USD 5.14 billion
Forecast Year [2030] USD 9.09 billion
CAGR (%) 9.95%

Key growth factors influencing the market include technological advances in diagnostic procedures, a robust pipeline of drugs, increasing investments in R&D, and government initiatives supporting cancer research. Additionally, collaborations between biotechnology firms and research institutions are creating potential opportunities, especially in personalized medicine and biomarker discovery. Recommendations to capitalize on these opportunities involve strategic partnerships, focusing on niche segments such as precision medicine, and accelerating clinical trials for promising therapies.

However, the market faces limitations such as high treatment costs, stringent regulatory approvals, and challenges in early diagnosis, which impact patient access to therapies. Competitive rivalry and significant time investments in drug development pose further hurdles. Firms can drive innovation by concentrating research efforts on developing less invasive treatments, improving drug delivery systems, and exploring novel combination therapies. Moreover, leveraging AI and big data analytics to enhance drug discovery efficiency is promising.

In conclusion, while the pancreatic cancer therapeutics market offers substantial opportunities for growth through technological advancements and collaborative efforts, addressing cost barriers and regulatory challenges will be crucial. Innovation in treatment modalities and data-driven approaches will pave the way for significant breakthroughs, facilitating business growth and improved patient care.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pancreatic Cancer Therapeutics Market

The Pancreatic Cancer Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of pancreatic cancer cases across the world
    • Government initiatives to expand access to pancreatic cancer treatment options
  • Market Restraints
    • Adverse drug recalls and difficulty in availing reimbursement options
  • Market Opportunities
    • Research initiatives and advancements to improve the efficacy of pancreatic cancer therapeutics
    • Approvals for pancreatic cancer therapy and orphan drug approvals for cancer treatment
  • Market Challenges
    • Limitations and complications of pancreatic cancer treatment options and lack of trained medical professionals

Porter's Five Forces: A Strategic Tool for Navigating the Pancreatic Cancer Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pancreatic Cancer Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pancreatic Cancer Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pancreatic Cancer Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pancreatic Cancer Therapeutics Market

A detailed market share analysis in the Pancreatic Cancer Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pancreatic Cancer Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pancreatic Cancer Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Pancreatic Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Amgen Inc., Ascentage Pharma Group, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Carl Zeiss AG, Carrick Therapeutics Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Faeth Therapeutics, Inc., FUJIFILM Holdings Corporation, GE HealthCare Technologies, Inc., GenesisCare, GlaxoSmithKline PLC, Hetero Healthcare Limited, ImmunityBio, Inc., Innovent Biologics Inc., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Mitsubishi Heavy Industries, Ltd., NGM Biopharmaceuticals, Inc., NovalGen, Novartis AG, PanTher Therapeutics, Inc., Pfizer, Inc., RenovoRx, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Zentalis Pharmaceuticals, Inc..

Market Segmentation & Coverage

This research report categorizes the Pancreatic Cancer Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Endocrine Pancreatic Cancer and Exocrine Pancreatic Cancer.
  • Based on Product, market is studied across Chemotherapy, Gene Therapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy.
  • Based on End-Use, market is studied across Cancer Centers/Clinics, Hospitals, and Research Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of pancreatic cancer cases across the world
      • 5.1.1.2. Government initiatives to expand access to pancreatic cancer treatment options
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse drug recalls and difficulty in availing reimbursement options
    • 5.1.3. Opportunities
      • 5.1.3.1. Research initiatives and advancements to improve the efficacy of pancreatic cancer therapeutics
      • 5.1.3.2. Approvals for pancreatic cancer therapy and orphan drug approvals for cancer treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations and complications of pancreatic cancer treatment options and lack of trained medical professionals
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Need for rapid deployment of therapeutic options due to fast progression of exocrine pancreatic cancer
    • 5.2.2. Product: Expanding number of approvals for chemotherapy treatment options
    • 5.2.3. End-Use: Expanding presence of collaborations and R&D initiatives in research institutes for pancreatic cancer treatment
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pancreatic Cancer Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Endocrine Pancreatic Cancer
  • 6.3. Exocrine Pancreatic Cancer

7. Pancreatic Cancer Therapeutics Market, by Product

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Gene Therapy
  • 7.4. Immunotherapy
  • 7.5. Radiation Therapy
  • 7.6. Surgery
  • 7.7. Targeted Therapy

8. Pancreatic Cancer Therapeutics Market, by End-Use

  • 8.1. Introduction
  • 8.2. Cancer Centers/Clinics
  • 8.3. Hospitals
  • 8.4. Research Institutes

9. Americas Pancreatic Cancer Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Pancreatic Cancer Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Pancreatic Cancer Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients
    • 12.3.2. Lisata Receives Orphan Drug Designation For Pancreatic Cancer Therapy
    • 12.3.3. PanCAN Announces New & Advanced Research Investment
    • 12.3.4. Prestige Biopharma and Imagion Biosystems Sign Partnership Agreement to Develop Early Pancreatic Cancer Diagnosis Platform
    • 12.3.5. TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation
    • 12.3.6. Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics
    • 12.3.7. Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy
    • 12.3.8. FDA Grants Breakthrough Therapy Designation to Zenocutuzumab for NRG1+ Pancreatic Cancer
    • 12.3.9. FDA Clears TME Pharma's IND for Pancreatic Cancer Therapy Trial
    • 12.3.10. GenesisCare Launches ViewRay MRIdian MRI-Guided Radiation Therapy System at Lee Health Regional Cancer Center
    • 12.3.11. USD 3 Million National Grant to Fund Pancreatic Cancer Study
    • 12.3.12. Leap Therapeutics Acquires Flame Biosciences
    • 12.3.13. Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
    • 12.3.14. Faeth Therapeutics Raises USD 47 million to Advance Clinical Trials for Cancer
    • 12.3.15. AstraZeneca-Merck's Lynparza Wins EU Approval for Pancreatic Cancer

Companies Mentioned

  • 1. Abbvie Inc.
  • 2. Amgen Inc.
  • 3. Ascentage Pharma Group
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca PLC
  • 6. Bristol-Myers Squibb Company
  • 7. C.H. Boehringer Sohn AG & Co. KG
  • 8. Carl Zeiss AG
  • 9. Carrick Therapeutics Limited
  • 10. Cipla Limited
  • 11. Dr. Reddy's Laboratories Ltd.
  • 12. Eli Lilly and Company
  • 13. F. Hoffmann-La Roche AG
  • 14. Faeth Therapeutics, Inc.
  • 15. FUJIFILM Holdings Corporation
  • 16. GE HealthCare Technologies, Inc.
  • 17. GenesisCare
  • 18. GlaxoSmithKline PLC
  • 19. Hetero Healthcare Limited
  • 20. ImmunityBio, Inc.
  • 21. Innovent Biologics Inc.
  • 22. Johnson & Johnson Services, Inc.
  • 23. Lupin Limited
  • 24. Merck & Co., Inc.
  • 25. Mitsubishi Heavy Industries, Ltd.
  • 26. NGM Biopharmaceuticals, Inc.
  • 27. NovalGen
  • 28. Novartis AG
  • 29. PanTher Therapeutics, Inc.
  • 30. Pfizer, Inc.
  • 31. RenovoRx, Inc.
  • 32. Sun Pharmaceutical Industries Ltd.
  • 33. Teva Pharmaceutical Industries Ltd.
  • 34. Zentalis Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. PANCREATIC CANCER THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PANCREATIC CANCER THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PANCREATIC CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PANCREATIC CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PANCREATIC CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PANCREATIC CANCER THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY ENDOCRINE PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY EXOCRINE PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY CANCER CENTERS/CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM PANCREATIC CANCER THERAPEUTICS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 148. PANCREATIC CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. PANCREATIC CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023